Treprostinil Sodium Injection

Abstract

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2002 monograph topics are adefovir dipivoxil, ximelagatran, agalsidase alfa and agalsidase beta, pemetrexed, and emtricitabine. The DUE is on adefovir dipivoxil.

Get full access to this article

View all access options for this article.

References

FDA Advisory Committee recommends approval of Remodulin for pulmonary arterial hypertension. Doctor's Guide to the Internet. August 10, 2001. www.docguide.com Accessed on August 10, 2001.

Remodulin [package literature]. United Therapeutics Corp.; March 2002.

Product Pipeline: Clinical Trial Status. United Therapeutics Corp.; May 23, 2002. www.unither.com/products/pipeline.asp. Accessed on May 23, 2002.

Mohler

E.R.

Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Vasc Med. 2000; 5: 231–7.

Patterson

J.H.

Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure. Am J Cardiol. 1995; 75: 26S–33A.

Gaine

S.P.

Acute hemodynamic effects of 15AU81, a stable epoprostenol analogue, in severe primary pulmonary hypertension [abstract]. Am J Respir Crit Care Med. 1998; 157(3 suppl).

Burnham

T.H.

, Wickersham

(eds.). Drug Facts and Comparisons: Efacts Edition. St. Louis, MO: Facts & Comparisons, Inc.; 2002.

Karkowsky

Clinical review. NDA: 21–272. Division of Cardio-Renal Drug Products. Center for Drug Evaluation and Research. Food and Drug Administration. March 20, 2001.

Clapp

L.H.

Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Resp Cell Mol Biol. 2002; 26: 194–201.

10.

Gaine

S.P.

Acute hemodynamic effects of subcutaneous UT 15 in primary pulmonary hypertension [abstract]. Am J Respir Crit Care Med. 1999; 159(3, suppl): A161.

11.

Emery

C.J.

Pulmonary vasodilation by airway delivered prostacyclin analogues, UT-15 & pegylated UT-15 [abstract]. Thorax. 2000; 55(suppl 3): P43.

12.

Findlay

J.W.

Radioimmunoassay for the chemical stable prostacyclin analog, 15AU81: A preliminary pharmacokinetics study in the dog. Prostaglandins Leukot Essent Fatty Acids. 1993; 48: 167–74.

13.

Simonneau

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Resp Crit Care Med. 2002; 165: 800–4.

14.

Barst

R.J.

Efficacy and safety of chronic subcutaneous infusion UT-15 in pulmonary arterial hypertension (PAH) [abstract]. Circulation. 2000; 102(18, suppl): 477.

15.

Oudiz

R.J.

Treprostinil (Remodulin) in connective tissue disease associated pulmonary hypertension [abstract]. Arthritis Rheum. 2001; 44(12): 2946-LB-4.

16.

McLaughlin

V.V.

Continuous subcutaneous infusion of Remodulin, a prostacyclin analogue, in patients with pulmonary arterial hypertension: Long-term outcome [abstract]. Circulation. 2001; 104(17, suppl): 109820.

17.

McLaughlin

V.V.

Long-term hemodynamic and exercise effects of UT-15, a subcutaneous prostacyclin analogue [abstract]. Circulation. 2001; 104(17, suppl): 115031.

18.

Barst

R.J.

Efficacy of long-term subcutaneous infusion of UT-15 in primary pulmonary hypertension [abstract]. Eur Heart J. 2000; 21(suppl): 315.

19.

Vachiery

J.L.

Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest. 2002; 121: 1561–5.

20.

United Therapeutics receives FDA approval for Remodulin to treat pulmonary arterial hypertension. PRNewswire. May 22, 2002. www.prnewswire.com. Accessed on May 23, 2002.

21.

Temple

Approval letter for Remodulin (NDA 21–272). Food and Drug Administration. May 2002. http://www.fda.gov/cder/foi/appletter/2002/21272ini.pdf. Accessed on June 4, 2002.

22.

Gentiva Health Services begins distribution of newly-approved therapy for pulmonary arterial hypertension. PRNewswire. May 23, 2002. www.prnewswire.com. Accessed on May 23, 2002.